In its first update on infection numbers in almost a year, this month, the city's-state’s state health ministry the estimated number of cases jumped 28% to 14,200 in the week through May 3 ...

From tokenisation and digital assets to AI-first banking, Dubai is rewriting the rules of finance. With a bold regulatory ...

Minority owner Partners Group say the IPO proceeds will be used to further grow the Hangzhou-headquartered restaurant's ...

Chinese biotech company Bliss Biopharmaceutical (BlissBio) is reportedly considering a Hong Kong initial public offering (IPO ...

CATL’s 6.7 per cent discount to its Shenzhen-traded shares is much lower than the average 25 per cent discount for ...

Shares of the restaurant chain began trading at HK$7.19 per share, unchanged from the offer price, before plunging 7 per cent ...

Now, with tensions easing and the US$43.6 billion ($56.62 billion) raised in 2025 IPOs so far running just behind the same ...

SINGAPORE] Singapore biotech start-up Mirxes launched its initial public offering (IPO) in Hong Kong on Thursday (May 15) as ...

Hillhouse’s HHLR Fund and its affiliated entities offloaded 16 million of BeiGene’s shares traded outside the Chinese ...

BEIJING] Ant Group’s quarterly profit fell 31 per cent as the firm invested in artificial intelligence and other initiatives ...

Trading in the shares is expected to start on May 23. Read more at straitstimes.com. Read more at straitstimes.com.

Jiangsu Hengrui Pharmaceuticals is planning to raise as much as US$1.27 billion via an initial public offering in Hong Kong, joining a wave of Chinese companies seeking to tap the city's market.